Last updated: June 17, 2026
Vertex Pharmaceuticals v. MSN Pharmaceuticals (1:26-cv-00306): Litigation Summary, Claims at Issue, and Near-Term Patent/ANDA Exposure
Vertex Pharmaceuticals Incorporated sued MSN Pharmaceuticals Inc. in the US District Court for the District of Delaware under docket 1:26-cv-00306. The matter centers on Vertex’s patent and regulatory exclusivity position for a product in the payer- and formulary-critical segment of Vertex’s portfolio and targets MSN’s US regulatory pathway conduct that is tied to that portfolio. A clean litigation-and-IP exposure view requires docket, complaint, and claim-by-claim document access; that level of case-specific detail is not present in the provided record.
What this means operationally
- Without the complaint, AT/answer, case schedule, asserted patent list, and FDA regulatory filings in the record, a defensible summary cannot identify:
- which Orange Book patents Vertex asserted,
- whether the case is an ANDA (Paragraph IV) or another Hatch-Waxman vehicle,
- the specific claims (independent/dependent) and technology (API, polymorph, formulation, method-of-use),
- the jurisdictional basis for the infringement count(s),
- whether there is a carve-out for FDA approval timing or a stipulated exclusivity carve,
- whether Vertex sought injunctive relief tied to the FDA approval date or approval letter.
- Under litigation strategy standards, any attempt to name asserted patents or claims without the cited filings would be speculative, which cannot be used for decisioning.
What patents are asserted in Vertex v. MSN Pharmaceuticals 1:26-cv-00306?
Answer: Not determinable from the information provided.
Patent estate mapping
A complete mapping for this docket requires the complaint’s “Patents-in-Suit” section and the attachment identifying the asserted claims. With that absent, the patent estate cannot be enumerated.
Claim-type categorization (data unavailable)
To classify the asserted claims, the complaint must specify whether Vertex is asserting:
- composition of matter patents (API, polymorph, crystal form),
- formulation patents (excipients, dosage form, film coating, controlled release),
- manufacturing method patents,
- method-of-use patents tied to patient selection or dosing regimen.
Is this case an ANDA Paragraph IV challenge, and what FDA milestone is at risk?
Answer: Not determinable from the information provided.
What typically drives timing in Hatch-Waxman
A litigation summary becomes actionable when it states:
- the ANDA number and filer (MSN),
- the listed reference product,
- the Orange Book patents and the Paragraph IV statements,
- whether Vertex sought a 30-month stay (or whether it had already expired),
- the current FDA status of the application and whether an approval letter exists.
No such filings or FDA identifiers are present in the provided record.
When does the exclusivity or patent window expire in Vertex v. MSN Pharmaceuticals?
Answer: Not determinable from the information provided.
Exclusivity and patent timeline framework (needs docket-specific identifiers)
For each asserted reference product, litigation decisions depend on:
- the last date of 5-year new chemical entity exclusivity (if applicable),
- 3-year new clinical investigation exclusivity,
- patent expirations for the Orange Book listings,
- any pediatric exclusivity extensions,
- potential terminal disclaimers and prosecution history effects.
These require the asserted product and patent numbers.
How strong is Vertex’s patent estate in this case?
Answer: Not determinable from the information provided.
What strength assessment requires
A true strength view uses:
- claim scope breadth (independent claim technical limits),
- whether the asserted claims target “design-around” sensitive features,
- cited prior art in the litigation record,
- known PTAB history (inter partes review outcomes),
- obviousness and enablement posture,
- whether MSN has non-infringement or invalidity defenses tied to specific claim elements.
None of that exists in the provided record.
What generic entry risks exist for MSN Pharmaceuticals based on 1:26-cv-00306?
Answer: Not determinable from the information provided.
Entry-risk checklist
To quantify launch risk, the litigation summary must include:
- whether MSN is a first-filer,
- whether the case is resolved with a settlement that converts to an authorized launch date,
- whether Vertex obtained a preliminary injunction (or a denial creates a path to approval),
- whether the FDA approval triggers are aligned to the claimed patent list.
These are not provided.
What litigation events matter most in Vertex v. MSN Pharmaceuticals?
Answer: Not determinable from the information provided.
Events typically summarized
- complaint filing date and plaintiffs’ initial asserted patent list,
- answer or dispositive motion deadlines,
- Markman schedule,
- claim construction outcomes,
- preliminary injunction hearing posture,
- stay orders tied to PTAB or co-pending matters,
- trial scheduling.
No docket events are included in the record.
Has there been a settlement or consent judgment in 1:26-cv-00306?
Answer: Not determinable from the information provided.
What settlement summaries should contain
- settlement date,
- whether it is “entry-for-release” (license or covenant),
- agreed launch date and scope (patent-specific),
- payment and non-monetary terms (if any),
- mutual dismissal and stipulation scope,
- confidentiality limits.
None of this appears in the provided record.
What is the Orange Book status of the reference product at issue here?
Answer: Not determinable from the information provided.
Orange Book dependency
An Orange Book status section must list:
- listed drug product name,
- application number(s),
- each listed patent number,
- patent expiration dates,
- pediatric exclusivity,
- exclusivity type dates,
- whether the listing is under “drug substance,” “drug product,” or “method of use.”
No reference product name or Orange Book listing identifiers are present.
How does Vertex’s position in this docket compare with other Vertex Hatch-Waxman cases?
Answer: Not determinable from the information provided.
Comparison requires dossier-level identification
A comparison needs:
- the asserted patents across dockets,
- settlement patterns,
- injunction patterns,
- repeat counsel and recurring technical claim targets.
None of those inputs are present.
Key Takeaways
- No case-specific litigation details (asserted patents, claims, FDA application identifiers, exclusivity/patent dates, procedural posture, settlement status) are available in the provided record for Vertex Pharmaceuticals Incorporated v. MSN Pharmaceuticals Inc., 1:26-cv-00306.
- A litigation summary suitable for licensing, litigation strategy, or generic entry planning cannot be produced without the complaint and docket filings that identify patents-in-suit and the FDA-related triggers.
FAQs
- What patents are typically asserted by Vertex in Hatch-Waxman suits against generic filers?
- How does the 30-month stay rule apply when a Paragraph IV ANDA is filed and sued?
- What claim types (composition, formulation, method-of-use) most often survive invalidity challenges in Hatch-Waxman litigation?
- What information in an infringement complaint determines whether a court will grant a preliminary injunction?
- How do FDA regulatory approvals interact with settlement covenants and agreed launch dates?
References
- Federal court case docket: Vertex Pharmaceuticals Incorporated v. MSN Pharmaceuticals Inc., 1:26-cv-00306.
